HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Will Crack Down On GMP Ingredient, Contaminant Spec Requirements

This article was originally published in The Tan Sheet

Executive Summary

GMP inspectors will begin more aggressively enforcing requirements for ingredient and contaminant specifications, FDA’s Fabricant warns. Recalls for undeclared allergens, salmonella and other pathogens are emerging more frequently as well.

You may also be interested in...



Protein Powder Firm Faces Criminal Charges From Economic Adulteration

American Pure Whey says on its website, "we are temporarily discontinuing the sale of products. Please check back in 7 days and you will be able to order our products." But firm previously warned by FDA about GMP deficiencies might want to recalculate how long sales will be stopped due to 41-count indictment on criminal charges.

Spiked “Supplements” For Diabetes, Pain On The Rise

FDA is seeing supplements spiked with Rx ingredients indicated for pain management and diabetes treatment, and needs industry help identifying violators, CFSAN head Michael Landa says.

Basic GMP Failures Will Prompt Heightened FDA Scrutiny

FDA supplement programs director Dan Fabricant and food and drug law attorney Marc Ullman reflect on the ongoing struggles of many supplement firms to meet good manufacturing practice standards. “‘I don’t have the resources to comply’ is not an excuse. Then get out of the business,” Ullman says.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel